Progress for Biomerica in Expanding Access to IBS Solutions
- Application signals a major step toward enhancing patient access to inFoods IBS
- inFoods IBS identifies specific foods that may trigger IBS symptoms such as bloating, abdominal pain, diarrhea, and constipation
Biomerica, Inc. (NASDAQ: BMRA), a pioneering biomedical company focused on advanced diagnostic solutions, has recently made significant progress towards improving patient access to its inFoods IBS product. The company, in collaboration with its CLIA laboratory partner, has submitted a request to the American Medical Association (AMA) for a Proprietary Laboratory Analysis (PLA) code specifically for the inFoods IBS diagnostic test. If approved, this code will be instrumental in facilitating claims submission for Medicare and other insurers, thereby broadening patient access to this personalized test aimed at managing Irritable Bowel Syndrome (IBS).
Strategic Milestone Toward Reimbursement
The application for a PLA code marks a crucial component of Biomerica's strategy to support the commercialization and accessibility of inFoods IBS. Establishing this code will streamline the process of claims submission and enhance the transparency of how the inFoods IBS test is billed to insurers. This achievement is expected to significantly increase the number of patients who could gain access to this innovative diagnostic tool.
"The submission of the PLA code application highlights our commitment to growing our impact in the healthcare sector," stated Zack Irani, CEO of Biomerica. "Obtaining insurance reimbursement is key to accelerating physician adoption of the inFoods IBS test, expanding patient access, and ultimately realizing the full commercial potential of our technology. Having a specific test code will aid insurers in processing claims for inFoods IBS effectively."
Meeting the Needs of IBS Patients
The inFoods IBS test offers a groundbreaking, non-invasive method to identify foods that can trigger IBS symptoms. By analyzing immune responses to certain foods, this test empowers healthcare providers to deliver tailored dietary recommendations aimed at alleviating IBS symptoms. Unlike traditional approaches that often rely on general dietary restrictions or medications to mask symptoms, the inFoods IBS test offers a personalized roadmap to better health.
IBS is a condition that affects approximately 10% to 15% of adults in the United States, contributing to substantial healthcare expenditures. The inFoods platform addresses a critical demand for effective management solutions within this underserved patient population.
Clinical Validation and Adoption Efforts
Recent clinical research published in a leading gastrointestinal journal has provided compelling evidence for the effectiveness of the inFoods IBS test. In a randomized clinical trial, patients who received personalized dietary guidance based on their test results reported significantly greater symptom relief compared to those on a placebo diet. Such findings underscore the potential of the inFoods platform to profoundly enhance the quality of life for individuals living with IBS.
To further drive the adoption of the inFoods IBS test, Biomerica is actively collaborating with esteemed gastroenterology groups and healthcare systems. Notably, the test is also accessible for direct-to-consumer ordering, which enhances availability for individuals seeking wellness solutions outside traditional medical settings.
Long-Term Value Creation for Patients and Stakeholders
Biomerica is optimistic that insurance reimbursement, supported by growing clinical validation, will solidify inFoods IBS as a pioneering diagnostic solution within the market. This application is just one of many initiatives Biomerica is launching to realize the vision of personalized, non-pharmaceutical approaches to managing healthcare challenges.
With the inFoods platform, Biomerica aims to revolutionize the diagnosis and treatment of IBS and potentially other gastrointestinal issues, delivering significant value to patients, healthcare providers, and investors alike.
About Biomerica and inFoods Technology
Biomerica, Inc. (NASDAQ: BMRA) is a global biomedical technology firm specializing in the development and marketing of advanced diagnostic and therapeutic products designed for use at the point of care and in clinical settings. Our mission is to enhance health outcomes while minimizing total healthcare costs. Biomerica focuses on gastrointestinal and inflammatory illnesses, with an array of diagnostic and therapeutic developments in the pipeline.
The inFoods IBS test employs a straightforward blood sample to evaluate a patient's immune response to particular foods. This method offers targeted, patient-specific guidance, enabling clinicians to identify trigger foods for IBS. The inFoods IBS test has undergone examination in leading clinical institutions, yielding promising results that suggest it can improve symptoms effectively compared to existing treatment options.
Frequently Asked Questions
What is the significance of the PLA code application for inFoods IBS?
The PLA code application is a critical step toward securing insurance coverage, which would enable more patients to access the inFoods IBS test.
How does the inFoods IBS test work?
The test identifies specific foods that trigger IBS symptoms by measuring the immune response using a simple blood sample.
What are the potential benefits of the inFoods IBS test?
This test offers personalized dietary recommendations that can significantly alleviate IBS symptoms, providing an alternative to traditional medications.
Who is Biomerica?
Biomerica, Inc. is a biomedical technology company dedicated to developing innovative diagnostic and therapeutic products, focusing on gastrointestinal health.
How can I order the inFoods IBS test?
The inFoods IBS test is available for direct-to-consumer ordering, making it accessible to those looking for proactive health solutions.
